Nektar Therapeutics (NKTR) Stock Price, Quote & News

Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is...

Industry: Biotechnology

Sector: Healthcare

Phone: 415 482 5300

Fax: 415 339 5300

Website: www.nektar.com

Address:

455 Mission Bay Boulevard South, San Francisco, United States

murphylaw Jan. 14 at 12:47 PM

$NKTR I'll enter at 26 in a couple of months.

0 · Reply

calbucs Jan. 13 at 6:57 PM

$NKTR We need some news , this drop is insane . Let’s go Leadership , fight back !!

1 · Reply

BK217 Jan. 13 at 6:52 PM

$NKTR bought 5000@~36 today. Increases my basis and perhaps am playing “catch a falling knife” but seems like this sell off is way overdone

1 · Reply

george4it Jan. 13 at 6:30 PM

$NKTR The selling continues with no news and at this rate I hate to say it but I don’t see why it wouldn’t dip down to fill the gap at 30.

0 · Reply

CH_Expat Jan. 13 at 5:57 PM

$NKTR Interested here in the high 20s. We will see if the gap fills.

0 · Reply

autographic Jan. 13 at 5:25 PM

$NKTR Green candle 🚨. 36

1 · Reply

Stonky_Mcprofitface Jan. 13 at 4:51 PM

RATINGS ALERT Stonkey McProfitface lowers $NKTR rating to “ITole Ya” from “GTFO!” Price target: Fuck.

0 · Reply

Stonky_Mcprofitface Jan. 13 at 4:42 PM

$NKTR I shorted this at $46

0 · Reply

Edenlaor Jan. 13 at 4:24 PM

$NKTR WTF?!

0 · Reply

Stonky_Mcprofitface Jan. 13 at 4:22 PM

$NKTR Aw.

0 · Reply

Nektar Therapeutics: Alopecia Update And A Look At The Road Ahead For Rezpeg

Dec 16, 2025, 1:29 PM EST - 4 weeks ago

Nektar Therapeutics (NKTR) Discusses Topline Results From REZOLVE-AA Phase 2b Study of rezpegaldesleukin in Alopecia Areata Transcript

Dec 16, 2025, 11:30 AM EST - 4 weeks ago

Nektar Alopecia Trial Misses Endpoint, Hits Significance After Patient Exclusion

Dec 15, 2025, 6:00 PM EST - 4 weeks ago

Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Induction Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on December 16, 2025

Dec 5, 2025, 6:00 PM EST - 5 weeks ago

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 12, 2025, 10:59 AM EST - 2 months ago

Nektar Therapeutics: Balancing The Immune System To Potential Blockbuster Markets

Nov 12, 2025, 12:39 AM EST - 2 months ago

Nektar Therapeutics: Cautiously Positive Moving Into Phase 2b Readout

Nov 8, 2025, 5:45 PM EST - 2 months ago

New Data from REZOLVE-AD Study of Rezpegaldesleukin Presented in Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting

Nov 7, 2025, 4:26 PM EST - 2 months ago

Nektar Therapeutics (NKTR) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 4:15 PM EST - 2 months ago

Nektar Therapeutics Reports Third Quarter 2025 Financial Results

Oct 30, 2025, 6:00 PM EDT - 2 months ago

Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

Oct 28, 2025, 6:00 PM EDT - 2 months ago

Nektar to Announce Financial Results for the Third Quarter on Thursday, November 6, 2025, After Close of U.S.-Based Financial Markets

Oct 28, 2025, 12:36 PM EDT - 2 months ago

San Francisco is making a comeback. So are these stocks from the City by the Bay

MAZE REAL

Oct 22, 2025, 8:00 AM EDT - 3 months ago

Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting

Sep 18, 2025, 2:31 PM EDT - 4 months ago

Why Is Nektar Therapeutics Stock Trading Lower On Thursday?

Sep 18, 2025, 8:45 AM EDT - 4 months ago

Nektar Presents New Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin in Late-Breaker Oral Presentation at EADV 2025

Sep 9, 2025, 7:00 AM EDT - 4 months ago

Nektar Announces REZOLVE-AD Phase 2b Results for Rezpegaldesleukin Selected for Late-Breaker Oral Presentation at EADV 2025

Sep 4, 2025, 2:52 PM EDT - 4 months ago

What's Going On With Nektar Therapeutics Stock On Thursday?

Sep 3, 2025, 7:00 PM EDT - 4 months ago

Nektar Therapeutics to Participate in Two Investor Conferences in September

Aug 8, 2025, 7:48 PM EDT - 5 months ago

Nektar Therapeutics (NKTR) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:15 PM EDT - 5 months ago

Nektar Therapeutics Reports Second Quarter 2025 Financial Results

Jul 31, 2025, 6:00 PM EDT - 5 months ago

Nektar to Announce Financial Results for the Second Quarter on Thursday, August 7, 2025, After Close of U.S.-Based Financial Markets

Jul 29, 2025, 9:00 AM EDT - 6 months ago

Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Severe-to-Very Severe Alopecia Areata

Jul 2, 2025, 4:15 PM EDT - 6 months ago

Nektar Therapeutics Announces Closing of $115 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Jul 1, 2025, 7:17 AM EDT - 7 months ago

Nektar Therapeutics Announces Pricing of $100 Million Public Offering

Jun 30, 2025, 4:02 PM EDT - 7 months ago

Nektar Therapeutics Announces Proposed Public Offering

Jun 27, 2025, 8:45 AM EDT - 7 months ago

Nektar Therapeutics Scores Big Phase 2b Win With Rezpeg

Jun 25, 2025, 1:42 PM EDT - 7 months ago

Why Is Nektar Therapeutics Stock Trading Higher On Wednesday?

Jun 24, 2025, 1:20 PM EDT - 7 months ago

Nektar Therapeutics Is Up 150%: What's Happening With NKTR Stock?

Jun 24, 2025, 7:35 AM EDT - 7 months ago

Nektar Therapeutics' experimental eczema drug meets main goals of mid-stage trial

Jun 24, 2025, 7:30 AM EDT - 7 months ago

REZOLVE-AD Phase 2b Study of Rezpegaldesleukin Meets Primary and Key Secondary Endpoints in Patients with Moderate-to-Severe Atopic Dermatitis

Jun 23, 2025, 4:30 PM EDT - 7 months ago

Nektar to Announce Top-line Data from the 16-Week Induction Period in REZOLVE-AD Phase 2b Study of Rezpegaldesleukin, a Regulatory T-cell Proliferator, in Atopic Dermatitis on June 24, 2025

Jun 11, 2025, 3:13 PM EDT - 7 months ago

Nektar Therapeutics: 2 Data Readouts For REZPEG 2025 Could Establish Further POC

Jun 10, 2025, 5:26 PM EDT - 7 months ago

AMBROSIA & NEKTAR Introduces Premium High-End Organic Food from Greece with a Commitment to Purity and Provenance

May 13, 2025, 5:00 PM EDT - 8 months ago

Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference

May 8, 2025, 10:08 PM EDT - 8 months ago

Nektar Therapeutics (NKTR) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:15 PM EDT - 8 months ago

Nektar Therapeutics Reports First Quarter 2025 Financial Results

May 1, 2025, 6:00 PM EDT - 9 months ago

Nektar to Announce Financial Results for the First Quarter on Thursday, May 8, 2025, After Close of U.S.-Based Financial Markets

Mar 20, 2025, 6:00 PM EDT - 10 months ago

Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Mar 12, 2025, 8:00 PM EDT - 10 months ago

Nektar Therapeutics (NKTR) Q4 2024 Earnings Call Transcript

Mar 12, 2025, 4:15 PM EDT - 10 months ago

Nektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 5, 2025, 6:00 PM EST - 11 months ago

Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2024 on Wednesday, March 12, 2025, After Close of U.S.-Based Financial Markets

Feb 26, 2025, 7:00 AM EST - 11 months ago

Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AA Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Severe-to-Very Severe Alopecia Areata

Feb 24, 2025, 7:00 AM EST - 11 months ago

Nektar Announces Clinical Trial Agreement to Evaluate Rezpegaldesleukin in Patients with New Onset Type 1 Diabetes Mellitus

Feb 24, 2025, 7:00 AM EST - 11 months ago

Nektar Therapeutics to Host Virtual Investor & Analyst Event with Type 1 Diabetes Experts on February 24th

Feb 10, 2025, 7:00 AM EST - 1 year ago

Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis

Jan 10, 2025, 7:00 AM EST - 1 year ago

Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AD Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Moderate-to-Severe Atopic Dermatitis

$Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting$

Dec 7, 2024, 12:00 PM EST - 1 year ago

Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting

Nov 18, 2024, 3:30 PM EST - 1 year ago

Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence

murphylaw Jan. 14 at 12:47 PM

$NKTR I'll enter at 26 in a couple of months.

0 · Reply

calbucs Jan. 13 at 6:57 PM

$NKTR We need some news , this drop is insane . Let’s go Leadership , fight back !!

1 · Reply

BK217 Jan. 13 at 6:52 PM

$NKTR bought 5000@~36 today. Increases my basis and perhaps am playing “catch a falling knife” but seems like this sell off is way overdone

1 · Reply

george4it Jan. 13 at 6:30 PM

$NKTR The selling continues with no news and at this rate I hate to say it but I don’t see why it wouldn’t dip down to fill the gap at 30.

0 · Reply

CH_Expat Jan. 13 at 5:57 PM

$NKTR Interested here in the high 20s. We will see if the gap fills.

0 · Reply

autographic Jan. 13 at 5:25 PM

$NKTR Green candle 🚨. 36

1 · Reply

Stonky_Mcprofitface Jan. 13 at 4:51 PM

RATINGS ALERT Stonkey McProfitface lowers $NKTR rating to “ITole Ya” from “GTFO!” Price target: Fuck.

0 · Reply

Stonky_Mcprofitface Jan. 13 at 4:42 PM

$NKTR I shorted this at $46

0 · Reply

Edenlaor Jan. 13 at 4:24 PM

$NKTR WTF?!

0 · Reply

Stonky_Mcprofitface Jan. 13 at 4:22 PM

$NKTR Aw.

0 · Reply

no_more_fake_news Jan. 13 at 4:09 PM

$NKTR A nice lly settlement would be great.

0 · Reply

george4it Jan. 13 at 3:46 PM

$NKTR being extra patient with this one. Data has not changed, so not sure why the continues selling other than traders working on the technicals.

0 · Reply

autographic Jan. 13 at 3:35 PM

$NKTR 🚨 Due for a bounce - trying this one .

0 · Reply

dayfornight99 Jan. 13 at 3:23 PM

$NKTR This going back to 30?

0 · Reply

BK217 Jan. 13 at 11:42 AM

$NKTR big jump in short interest 👀

0 · Reply

BK217 Jan. 13 at 2:07 AM

$NKTR this was pretty good 😆

2 · Reply

BK217 Jan. 13 at 12:46 AM

$NKTR lol

0 · Reply

george4it Jan. 12 at 8:49 PM

$NKTR Possible reversal based on buying activity seen in the afternoon. Need confirmation from trading action tomorrow.

0 · Reply

Zaksab Jan. 12 at 6:17 PM

$NKTR fugly fugly

0 · Reply

calbucs Jan. 12 at 5:23 PM

$NKTR From $67 plus to $37 plus in a month ? But it’s not manipulation though . 😉

0 · Reply

george4it Jan. 12 at 5:20 PM

$NKTR Might be at support level.

0 · Reply

Jorlev Jan. 12 at 5:17 PM

$NKTR When is next expected trial data for Nektar?????

0 · Reply

Market Cap	788.66M
Revenue (ttm)	98.43M
Net Income (ttm)	-118.96M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-120.86%
Debt to Equity Ratio	0.00

Volume	1,227,000
Avg Vol	820,744
Day's Range	N/A - N/A
Shares Out	20.34M
Stochastic %K	9%
Beta	1.31
Analysts	Strong Sell
Price Target	$114.43